Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral Formulation

Medicinal cannabis is prescribed in Australia for patients with chronic refractory pain conditions. However, measures of safety and effectiveness of different cannabinoids are lacking. We designed an observational study to capture effectiveness, adverse events (AEs), and health-related quality of life (HRQoL) measures in patients prescribed an oral medicinal cannabis formulation at Cannabis Access Clinics through the Cannabis Access Clinics Observational study (CACOS).

Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management

The current rate of opioid prescription is disquieting because of their high abuse potential, adverse effects, and thousands of overdose deaths. This situation imposes urgency in seeking alternatives for adequate pain management. From this perspective, this study aimed to evaluate the experience and the perceived analgesic efficacy of medical cannabis in managing the pain associated with musculoskeletal conditions.

Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions

Combination tetrahydrocannabinol (THC)/cannabidiol (CBD) medicines or CBD-only medicines are prospective treatments for chronic pain, stress, anxiety, depression, and insomnia. THC and CBD increase signaling from cannabinoid receptors, which reduces synaptic transmission in parts of the central and peripheral nervous systems and reduces the secretion of inflammatory factors from immune and glial cells.

Analgesic Potential of Terpenes Derived from Cannabis sativa

Decades of research have improved our knowledge of cannabis polypharmacy and contributing phytochemicals, including terpenes. Reform of the legal status for cannabis possession and increased availability (medicinal and recreational) have resulted in cannabis use to combat the increasing prevalence of pain and may help to address the opioid crisis. Better understanding of the pharmacological effects of cannabis and its active components, including terpenes, may assist in identifying new therapeutic approaches and optimizing the use of cannabis and/or terpenes as analgesic agents.

Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain

Chronic non-cancer pain (CNCP) is estimated to affect 20% of the adult population. Current United States and Canadian Chronic non-cancer pain guidelines recommend careful reassessment of the risk-benefit ratio for doses greater than 90 mg morphine equivalent dose (MED), due to low evidence for improved pain efficacy at higher morphine equivalent dose and a significant increase in morbidity and mortality. There are a number of human studies demonstrating cannabis opioid synergy. This preliminary evidence suggests a potential role of cannabis as an adjunctive therapy with or without opioids to optimize pain control.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.
To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study

Authors: Emily M.Webster, Ghanshyam S.Yadav, Stefan Gysler, Blair McNamara, Jonathan Black, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Christopher K. Arkfeld, Vaagn Andikyan, Gulden Menderes, Gloria Huang, Masoud Azodi, Dan-Arin Silasi, Alessandro D.Santin,Peter E.Schwartz, Elena S.Ratner, Gary Altwerger Published in Gynecologic Oncology Reports   November 2020 Abstract Research within a gynecologic oncology population has lagged behind…

Medical cannabis and cognitive performance in middle to old adults treated for chronic pain

Authors: Sharon R Sznitman, Simon Vulfsons, David Meiri, Galit Weinstein Published in Drug and Alcohol Review September 2020 Abstract Introduction and aims: Cannabis exposure is becoming more common in older age but little is known about how it is associated with brain health in this population. This study assesses the relationship between long-term medical cannabis…

Cannabis: An Emerging Treatment for Common Symptoms in Older Adults

Authors: Kevin H Yang, Christopher N Kaufmann, Reva Nafsu, Ella T Lifset, Khai Nguyen, Michelle Sexton, Benjamin H Han, Arum Kim, Alison A Moore Published in Journal of the American Geriatrics Society October 2020 Abstract Background/objectives: Use of cannabis is increasing in a variety of populations in the United States; however, few investigations about how…

Medical Cannabis Treatment for Chronic Pain: Outcomes and Prediction of Response

Authors: Joshua Aviram, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar, Adahan Haim‐Moshe, Silviu Brill, Howard Amital, Itay Goor‐Aryeh, Dror Robinson, Leslie Green, Refael Segal, Yacov Fogelman, Oren Tsvieli, Ben Yellin, Yelena Vysotski, Ofir Morag, Vadim Tashlykov, Roee Sheinfeld, Ruth Goor, David Meiri, Elon Eisenberg Published in European Journal of Pain…

Cannabis and Cannabidiol (CBD) for the Treatment of Fibromyalgia

Authors: Amnon A.Berger MD, PhD, Joseph Keefe BM, Ariel Winnick MA, Elasaf Gilbert BS, Jonathan P.Eskander MD, MBA, Cyrus Yazdi MD, Alan D.Kaye MD, PhD, Omar Viswanath MD, Ivan Urits MD Published in Science Direct  August 2020 Abstract Background Fibromyalgia is a complex disease process that is as prevalent as it is poorly understood. Research into…

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

Author: Alex Capano, Richard Weaver & Elisa Burkman Published in Postgraduate Medicine   November 2019 Abstract Context: Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy…

A Comprehensive Patient and Public Involvement Program Evaluating Perception of Cannabis-Derived Medicinal Products in the Treatment of Acute Postoperative Pain, Nausea, and Vomiting Using a Qualitative Thematic Framework

Author: Simon Erridge, Marie Miller, Tamara Gall, Antonio Costanzo, Barbara Pacchetti, and Mikael H. Sodergren Published in Mary Ann Liebert, Inc Publishers  February 2020 Abstract Introduction: Cannabis-derived medicinal products (CDMPs) have antiemetic properties and in combination with opioids have synergistic analgesic effects in part signaling through the delta and kappa opioid receptors. The objective of this patient…